Despite decreasing number of gastric cancer patients, prognoses of advanced gastric cancer are still poor. Some Rho GEF expressions are supposed to be higher in invasive cancer. Based on this hypothesis, we narrow down 72 Rho-GEF genes to 9 candidate genes by in silico method. Then we focused on FARP1 since it has never been reported to have clinical significance in cancers. From an immunohistochemical study of 91 cases of invasive gastric cancer, the overall survival of the patients with higher FARP1 expression cancer was significantly shorter than that in the patients with lower FARP1 cancer (P = 0.025). FARP1 expression is related to lymphatic metastasis (N) (P = 0.012), lymphatic invasion (P = 0.025) and recurrence rate (P = 0.002). In vitro study FARP1 high expression promoted gastric cancer cell motility, invasion with filopodium formation, and increase of GTP/CDC42, but did not increase proliferation. Integrinβ5 coprecipitated with FARP1 using anti-flag antibody. In the presence of 0.3 nM SB273005 Integrinβ5 inhibitor, filopodia formation and GTP/CDC42 activation in FARP1 expressing cells decreased. From these results, the Integrinβ5-FARP1-CDC42 cascade is related to the prognoses of advanced gastric cancer patients through the increase of cell motility and a new target of invasive cancer therapy.